Description
LIPANTHYL PENTA 145, film-coated tablet is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.
LIPANTHYL PENTA 145, film-coated tablet is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. Lipanthyl does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic.
Adults: The recommended dose is one tablet containing 145mg fenofibrate taken once daily. Patients currently taking one 200 mg capsule (or one 160 mg tablet) can be changed to one 145mg fenofibrate tablet without further dose adjustment.
Special Populations: Geriatric Populations: In elderly patients, without renal impairment, the usual adult dose is recommended.
Dosage reduction is required in patients with renal impairment. In moderate chronic kidney disease (creatinine clearance 30 to 60mL/min), and if a low dose is available, start with one capsule of 100mg standard once daily.
If no low dose is available, then fenofibrate is not recommended.
In patients with severe chronic kidney disease (creatinine clearance < 30ml/min), fenofibrate is contraindicated.
